Kurve Therapeutics, Inc. Announces Development of New Intellectual Property to Target Drug Delivery in the Brain

Led by a team of experienced entrepreneurs with successful track records in biotech, pharmaceuticals, neuroscience, and device technology, Kurve Therapeutics is paving the way for revolutionary clinical success in treating complex CNS disorders, including Alzheimer’s and Parkinson’s disease. The company recently announced new IP to target where medical formulations go in the brain.

LYNNWOOD, Wash., March 15, 2023 /PRNewswire/ — Today, Kurve Therapeutics (Kurve Tx) announced it has filed for new intellectual property on its nose-to-brain technology platform. Kurve’s technology uses the neuronal pathway rather than the circulatory system, which means the drug is delivered to the extracellular space in the brain. This means there is the opportunity to move the drug once it reaches the brain. The new IP will incorporate this ability allowing for treatments throughout the brain rather than just the frontal lobe. In contrast, the circulatory system traps the drug in the blood vessels blocking the opportunity to move the drug to a desired target.

Marc Giroux, CEO of Kurve Therapeutics, said, “We have been successfully delivering medications to the brain intranasally for more than a decade, and we learned a lot from the variety of formulations and conditions in which we have been involved. So, it gives me great pleasure to announce that we are developing technology that will allow us to target where the drug goes once it has been delivered to the brain. R&D is working diligently to get test results by the end of the year.”

Mr. Giroux further explained that while Kurve Therapeutics has proven successful at delivering medication to the frontal lobe with access to the hippocampus and, to some extent, to the brain stem, there was simply no way to focus delivery of medications to the sides, posterior, or center mass of the brain. He went on, “What happens if the condition was not frontally located, or a targeted tumor was toward the back of the brain? It is clear that we need the means to target these areas; we have filed a patent application covering a credible, promising solution. I believe we have figured it out.”

While performing this work, Mr. Giroux combined the chemistry, biology, and physics learned over the years into a solution for this critical issue. Since Kurve’s technology platform circumvents rather than uses the circulatory system (particularly with larger molecules), drugs are not confined to the bloodstream. Instead, clinicians will be able to relocate them within the cerebral spinal fluid (CSF) space surrounding the brain. This capability will allow for a greater concentration of drugs in the central nervous system, decreasing systemic exposure and broadening the therapeutic window. This outcome, in turn, expands the range of agents that could be viable CNS drugs. In addition, in a head-to-head measure in a clinical study in Southern California, Kurve’s technology delivered 3,000% more medication into the brain than an infusion. This result gives the formulators tremendous dose flexibility in the toxicity levels of the drug.

Delivering a drug to the brain and then relocating it to a target area should put Kurve Therapeutics at the vanguard of CNS and glioblastoma delivery and treatment. Kurve looks forward to working with its pharmaceutical partners to progress this new technology. Details on how the technology platform functions are available through Kurve Therapeutics under an NDA.

Kurve’s new IP can be seen at the upcoming LSI USA ’23 Emerging Medtech Summit in Dana Point, California from March 20–23, 2023.

About Kurve Therapeutics

Kurve Therapeutics, a medtech and drug formulation company, is the developer of Controlled Particle Dispersion® (CPD) intranasal drug delivery technology. This technology is designed to advance treatments for neurodegenerative diseases, including therapies with complex molecules such as monoclonal antibodies and larger peptides by allowing medication to cross the blood-brain barrier.

Eighteen peer-reviewed publications in leading medical journals have featured Kurve’s patented technology. CPD® has been used in five double-blind placebo-controlled Phase II studies and is ready for Phase III with Alzheimer’s patients.

Kurve has filed a Form 1-A preliminary offering circular with the U.S. Securities and Exchange Commission (SEC) for a Regulation A+ $50 million funding round [kurvetx.com/offering-circular]. Investment opportunities are now open to the general public for investments starting at $580 for 100 shares.

Sign Up Now to Invest With Kurve!

*Founders, board, and management own 51% of common shares

16825 48th West Suite 434
Lynnwood, WA 98037

(425) 640-9249

Transfer Agent: KoreConX Inc.  |  Broker-Dealer: Rialto Markets LLC  |  Escrow Agent: Wilmington Trust NA The Refund Policy: There are no refunds or cancelations of commitments once the subscription agreement is signed and submitted.  Please contact compliace@rialtomarkets.com with questions regarding a cancelation or refund.

  • Rialto Markets LLC is the Onboarding Agent for this offering and is not an affiliate of nor connected with the Issuer.
  • Rialto Markets LLC is NOT placing or selling these securities on behalf of the Issuer.
  • Rialto Markets LLC is NOT soliciting this investment nor making any recommendations by collecting, reviewing, and processing your application for investment.
  • Rialto Markets LLC conducts Anti-Money Laundering, Identity, and Bad Actor Disqualification reviews of the Issuer, and ensures they are a registered business in good standing.
  • Rialto Markets LLC is NOT validating or approving the information provided by the Issuer or the Issuer itself.
  • Contact information below is provided for applicants to make inquiries and requests of Rialto Markets LLC regarding the general application process, the status of the application, or general Reg A regulation-related information. Rialto Markets LLC may direct applicants to specific sections of the Offering Statement to locate information or answers to their inquiry but does not opine or provide guidance on Issuer-related matters.

The offering will be made only by means of an offering circular. An offering statement regarding this offering has been filed with the SEC. The SEC has qualified that offering statement which only means that the company may make sales of the securities described by that offering statement. It does not mean that the SEC has approved, passed upon the merits or passed upon the accuracy or completeness of the information in the offering statement. The securities offered by the company are highly speculative. Investing in shares of common stock of the company involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops following the offering, it may not continue. You may obtain a copy of the Form 1-A offering circular that is part of said offering statement here. You should read the offering circular before making any investment. The offering materials and this letter may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company’s management. When used in the offering materials, the words “estimate,” “project,” “believe,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements, which constitute forward-looking statements. These statements reflect management’s current views with respect to future events and are subject to risks and uncertainties that could cause the company’s actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.

This investment involves a high degree of risk. This investment is suitable only for persons who can bear the economic risk for an indefinite period of time and who can afford to lose their entire investment. Furthermore, investors must understand that such investment is illiquid and is expected to continue to be illiquid for an indefinite period of time. No public market exists for the securities.

This information is presented only for the purpose of providing a general overview of clinical trials. These uses have not been approved by the U.S. Food and Drug Administration (FDA) or other regulatory authorities.